---
layout: default
title: Melatonin
parent: 僅模型預測 (L5)
nav_order: 88
evidence_level: L5
indication_count: 0
---

# Melatonin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Melatonin: No Repurposing Predictions Available

## One-Sentence Summary

Melatonin is an endogenous neurohormone best known for regulating circadian rhythms and sleep-wake cycles, widely used as a supplement for insomnia and jet lag in many countries.
However, **this Evidence Pack contains no TxGNN repurposing predictions**, and no approved indications or market authorization records were found in Taiwan.
A full repurposing evaluation cannot be completed until the missing data is collected.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No regulatory records found in Taiwan |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — model prediction unavailable; no supporting studies |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The current Evidence Pack provides no TxGNN repurposing predictions, no approved indication records, no mechanism of action data, and no safety profile — the minimum information needed to conduct a meaningful repurposing evaluation is entirely absent.

**To proceed, the following is needed:**

- **TxGNN predictions**: Run the melatonin candidate through the TxGNN model to obtain disease–drug prediction scores and candidate indications
- **Mechanism of action (MOA)**: Query DrugBank API (DB01065) to retrieve pharmacological targets and pathway data
- **Original indication baseline**: Confirm approved indications via TFDA package insert or international label (e.g., EMA/FDA) since Taiwan has no registered products
- **Safety data**: Parse TFDA package insert PDF for warnings, contraindications, and special population guidance
- **Drug–drug interaction (DDI) profile**: Expand DDI query scope (e.g., DrugBank DDI endpoint, Lexicomp) as the current query returned no results

---

> **Note:** This report reflects the state of the Evidence Pack as of 2026-04-20. Melatonin is not classified as antineoplastic; no cytotoxicity section is required. All sections dependent on `predicted_indications` have been omitted per reporting rules, as that array is empty.
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

